Physician profile
Michael A Pace
NPI 1356352256
$1,933.56
in general payments reported to CMS, 2019-2025
27 companies · $208 in 2025
The $208 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $291 · 2021: $277 · 2022: $235 · 2023: $121 · 2024: $375 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $666 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $665.95 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $278.49 | 2020-2022 | |
| Pfizer INC. | $211.27 | 2019-2024 | |
| Novo Nordisk INC | $189.69 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $154.35 | 2019-2020 | |
| Mylan Specialty L.P. | $147.83 | 2022-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.72 | 2024 | |
| Abbvie INC. | $104.60 | 2021-2024 | |
| Astellas Pharma US INC | $88.57 | 2019-2023 | Veozah |
| Medtronic Minimed, INC. | $80.07 | 2019 | |
| Dexcom, INC. | $64.56 | 2021 | |
| Sanofi-Aventis U.S. LLC | $61.43 | 2019 | |
| Viatris Specialty LLC | $53.67 | 2025 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $52.31 | 2022 | |
| Eisai INC. | $48.37 | 2024 | |
| Genzyme Corporation | $46.78 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $38.54 | 2025 | Rexulti |
| Amgen INC. | $28.17 | 2019-2024 | Evenity, Prolia |
| Biohaven Pharmaceutical Holding Company Ltd. | $22.29 | 2022 | |
| Sunovion Pharmaceuticals INC. | $20.42 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.89 | 2024 | Quviviq |
| Boston Scientific Corporation | $16.48 | 2019 | |
| Antares Pharma, INC. | $15.16 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.96 | 2025 | Xifaxan |
| Pharming Healthcare, INC. | $14.36 | 2021 | |
| Lilly USA, LLC | $13.28 | 2024 | Mounjaro |
| Genentech USA, INC. | $13.17 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $13.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Pace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.